BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 19012927)

  • 1. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival.
    Nguyen CT; Reuther AM; Stephenson AJ; Klein EA; Jones JS
    J Urol; 2009 Jan; 181(1):75-80. PubMed ID: 19012927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer.
    Weight CJ; Reuther AM; Gunn PW; Zippe CR; Dhar NB; Klein EA
    Urology; 2008 Jan; 71(1):141-5. PubMed ID: 18242383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
    Tollefson MK; Blute ML; Rangel LJ; Karnes RJ; Frank I
    J Urol; 2010 Sep; 184(3):925-9. PubMed ID: 20643452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
    Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
    J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
    Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
    J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing nature of high risk patients undergoing radical prostatectomy.
    Kane CJ; Presti JC; Amling CL; Aronson WJ; Terris MK; Freedland SJ;
    J Urol; 2007 Jan; 177(1):113-7. PubMed ID: 17162017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
    Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
    Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary cryoablation nadir prostate specific antigen and biochemical failure.
    Levy DA; Pisters LL; Jones JS
    J Urol; 2009 Sep; 182(3):931-7. PubMed ID: 19616226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era.
    Boorjian SA; Karnes RJ; Crispen PL; Carlson RE; Rangel LJ; Bergstralh EJ; Blute ML
    J Urol; 2010 Mar; 183(3):1003-9. PubMed ID: 20092854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
    Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
    J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
    J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
    Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2001 Aug; 166(2):416-9. PubMed ID: 11458039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
    Khaksar SJ; Laing RW; Henderson A; Sooriakumaran P; Lovell D; Langley SE
    BJU Int; 2006 Dec; 98(6):1210-5. PubMed ID: 17034501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.